ADC Therapeutics SA (ADCT) - Total Assets
Based on the latest financial reports, ADC Therapeutics SA (ADCT) holds total assets worth $291.50 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ADC Therapeutics SA (ADCT) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ADC Therapeutics SA - Total Assets Trend (2016–2025)
This chart illustrates how ADC Therapeutics SA's total assets have evolved over time, based on quarterly financial data. Explore how much of ADC Therapeutics SA's assets are long-term investments to see how much of total assets are deployed in long-term investments.
ADC Therapeutics SA - Asset Composition Analysis
Current Asset Composition (December 2025)
ADC Therapeutics SA's total assets of $291.50 Million consist of 94.8% current assets and 5.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.9% |
| Accounts Receivable | $29.12 Million | 9.0% |
| Inventory | $4.18 Million | 1.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how ADC Therapeutics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of ADC Therapeutics SA.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ADC Therapeutics SA's current assets represent 94.8% of total assets in 2025, a decrease from 97.5% in 2016.
- Cash Position: Cash and equivalents constituted 80.9% of total assets in 2025, down from 92.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 9.0% of total assets.
ADC Therapeutics SA Competitors by Total Assets
Key competitors of ADC Therapeutics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Nanobiotix S.A
PA:NANO
|
France | €45.17 Million |
ADC Therapeutics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.09 | 4.46 | 7.66 |
| Quick Ratio | 4.02 | 4.16 | 7.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $209.14 Million | $200.19 Million | $342.93 Million |
ADC Therapeutics SA - Advanced Valuation Insights
This section examines the relationship between ADC Therapeutics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.42 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | 0.4% |
| Total Assets | $323.15 Million |
| Market Capitalization | $132.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values ADC Therapeutics SA's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ADC Therapeutics SA's assets grew by 0.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ADC Therapeutics SA (2016–2025)
The table below shows the annual total assets of ADC Therapeutics SA from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $323.15 Million | +0.36% |
| 2024-12-31 | $321.98 Million | -9.25% |
| 2023-12-31 | $354.78 Million | -27.72% |
| 2022-12-31 | $490.86 Million | -20.57% |
| 2021-12-31 | $617.97 Million | +20.30% |
| 2020-12-31 | $513.69 Million | +273.10% |
| 2019-12-31 | $137.68 Million | -8.55% |
| 2018-12-31 | $150.56 Million | -44.64% |
| 2017-12-31 | $271.95 Million | +75.36% |
| 2016-12-31 | $155.08 Million | -- |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatme… Read more